PERFORMANCE ANALYSIS Kalytera Therapeutics (OTC: KALTF) IN FOCUS:
The volatility or the average percentage of the real interval (ATRP 14) is 14.29%. The ATR expressed as a percentage of the closing price. The average of the real interval percentage (ATRP) measures volatility at a relative level. ATRP allows you to compare titles while ATR no. This means that low-priced shares will not necessarily have lower ATR values than higher-priced ones.
Kalytera Therapeutics (OTC: KALTF) made -1.857143% last month and achieved -1.857143% in the last quarter. The stock showed a return of -85.6875% over five years and recorded a weekly return of -1.857143%. The stock was seen at -47.153846% yield in the last twelve months.
Monitoring of the last 52 weeks, the high price of shares at 52 weeks was observed at $ 0.4544 and the minimum at 52 weeks seen at $ 0.056. The 50 SMA is $ 0.077064 and the 200 SMA is $ 0.095444. Moving averages can be used as support or resistance when a trader looks for a possible entry or exit on the market. This can also be said in the following way. In the event that the price makes a contact with the moving average on the price table, the trader, examining this chart carefully, will enter a long position or a short position. In reality, this works the same way as horizontal support or resistance lines. Moving averages are known as dynamic support and resistance, simply because they tend to change with prices.
Kalytera Therapeutics (OTC: KALTF) the stock changed $ 0.0062 and moved 9.92%, while the share price touched $ 0.0687 in the last commercial transaction (FRIDAY). 287959 shares traded by hand while it is an average volume with 25,3002 shares. The company recorded a relative volume of 1.14. When an analyst or investor is looking for a stock, it's good to know what other investors think of it. After all, they might have some more information about the company or they could create a trend. The most popular methods for assessing the market's opinion is to look at the recently traded volume.
.
EBITDA is $ -4784000. EBITDA is the income of a company before interest, taxes, depreciation and amortization and is an accounting measure calculated using the net profits of a company, before interest charges, taxes, amortization and depreciation are deducted as a proxy for profitability current of a company.
The company's net income is $ -24379000. Net income available to common stockholders equals net income minus the privileged dividends paid. The net profits available to the common shareholders are the remaining profits after the company pays all its suppliers, employees, service providers, creditors and preferred shareholders. In other words, it's all revenue minus all your favorite expenses and dividends. The number measures the credit of the common shareholders on the company's cash flows.
Return on invested capital (ROCE) is -7.84%. Return on investment (ROCE) is a financial report that measures the profitability of a company and the efficiency with which its capital is used. The return on invested capital (ROCE) is the total amount of capital that a company has used to generate profits. It is the sum of the net assets and liabilities of the debt. It can be simplified as a total of assets minus current liabilities.
The current ratio is 0.155. The current relationship is the classic measure of liquidity. Indicates if the company can pay the debts due within one year from current assets. The quick ratio is 0.155. 1: 1 shows that the company can meet its current financial obligations with quick funds at hand. A ratio of less than 1: 1 could indicate that the company relies too much on inventory or other assets to pay off its short-term liabilities.
The debt / equity shows a value of 340,123. The D / E ratio is calculated by dividing the total liabilities of a company by its own share capital. In general, a high debt / capital ratio means that a company may not be able to generate enough money to meet its debt obligations. However, low debt / capital ratios may also indicate that a company is not exploiting the greater profits that leverage can bring.
PROFITABILITY REPORT:
Monitoring of profitability control, company profit margin recorded at 0.00% and operating margin at 0.00%. The Company was able to maintain the return on the asset (ROA) at -10.04% in the last twelve months. Return on equity (ROE) recorded at -289.83%.
VALIDATION OBSERVATIONS:
Kalytera Therapeutics Headquarters (OTC: KALTF) is United States. The P / B ratio is 22.9. P / B is used to compare the market value of a security with its book value. It has a market capitalization of $ 15550589. Using market capitalization to show the size of a company is important because the size of the company is a basic determinant of various characteristics in which investors are interested, including the risk .
TECHNICAL INDICATORS:
Now the company has an RSI figure of 44.02. The RSI compares the entity of recent gains with recent losses to see if an asset is oversold or overbought. RSI is plotted on a scale of 0 to 100. Generally, if it is above 70, the stock is considered overbought and then you can try to sell it. Similarly, an RSI below 30 indicates that the stock is oversold and can be purchased.
ADX value listed in 35.26. ADX is best used for inventory screening and writing scans. By adding this indicator to the scanning software, it is possible to eliminate all the stocks that are in the trading ranges. You can then set the scan to find only stocks with a sharp uptrend or strong downtrend.
So what is the ADX indicator for?
The ADX indicator does not provide signals of purchase or sale. However, it gives you some perspective on where the title is in the trend. Low readings and you have a trading interval or the beginning of a trend. Extremely high readings indicate that the trend will probably end.
Larry Spivey – Category – Business
Larry Spivey it also covers economic news in all market sectors. He also has a huge knowledge of the stock market. He holds an MBA degree from the University of Florida. He has more than 10 years experience in writing financial and market news. Previously, Larry has worked in several companies with different roles including web developer, software engineer and product manager. Currently it deals with the Business news section.
